Overview
- The Justice Department filed the motion on Jan. 27 seeking to stay Louisiana’s suit targeting mail delivery of mifepristone and the FDA’s 2023 removal of the in-person dispensing rule.
- Government lawyers told the court that proceeding now would waste judicial resources and pledged to notify the judge within 14 days of any regulatory change arising from the review.
- A hearing is scheduled for Feb. 24 in federal court in Louisiana, where the state is also pressing for a preliminary order to restore the in-person requirement.
- The filing disputes Louisiana’s legal standing and points to the FDA’s ongoing review of mifepristone’s REMS, which Politico reported could conclude within about a year.
- Anti-abortion groups and Louisiana Attorney General Liz Murrill criticized the request as a delay tactic and urged immediate action to reinstate restrictions on the drug.